MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Zanubrutinib demonstrated a 5-year progression-free survival (PFS) rate of 72.2% and overall survival rate of 85.1% in patients with deletion of the 17p chromosome (del[17p]) chronic lymphocytic ...
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) The ...
Both time-limited therapy and continuous therapy for chronic lymphocytic leukemia (CLL) have potential benefits and drawbacks. The best choice, a joint decision between clinician and patient, should ...
ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...
The article by Davids et al entitled “A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease” (Journal of Clinical ...
Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...
Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...
One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients. By participating in clinical trials, patients with cancer have the opportunity to find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results